GLP-1 Receptor Agonist Use Linked to Reduced Colorectal Cancer Risk in IBD Patients

Findings presented at the 2026 ASCO Breakthrough Meeting in Singapore indicate that the use of GLP-1 receptor agonists is significantly associated with a lower five-year incidence of colorectal cancer among patients with inflammatory bowel disease (IBD), including those with concomitant type 2 diabetes. This observational study suggests a potential role for GLP-1 drugs in cancer prevention, though further prospective studies are needed to confirm a cause-and-effect relationship.